PMID- 9652825
OWN - NLM
STAT- MEDLINE
DCOM- 19980730
LR  - 20190818
IS  - 0300-9475 (Print)
IS  - 0300-9475 (Linking)
VI  - 47
IP  - 6
DP  - 1998 Jun
TI  - Immunoglobulin prolongs survival of pig kidneys perfused ex vivo with human 
      blood.
PG  - 568-74
AB  - Intravenous immunoglobulin (IVIG) (Octagam), was used to determine the effect on 
      hyperacute rejection in an ex vivo xenograft model. Six pig kidneys were perfused 
      with IVIG and fresh human AB blood, and six control pig kidneys were 
      simultaneously perfused with albumin and blood from the same donation. The 
      survival of the IVIG-perfused xenografts (median, 6.5 h) was significantly (P = 
      0.03) longer than the albumin-perfused xenografts (median, 3.5 h). Complement was 
      activated in both groups. The administration of IVIG to the perfused blood 
      resulted in immediate and significantly higher complement activation in the fluid 
      phase as compared with the albumin group. At rejection the fluid phase complement 
      activation was higher in the IVIG group than in the albumin group for C1rs/C1inh 
      complexes, C4bc, Bb and TCC. At the time of rejection both the albumin and the 
      IVIG group demonstrated interstitial tubular haemorrhage, vasculitis or necrosis 
      of glomerular capillaries and glomerular microthrombi. IgM, C1q, C3c, C4 and 
      fibrin were located in arteries and glomeruli and IgG in the interstitium in both 
      groups at rejection. The fluid phase findings are consistent with a modulatory 
      effect of IVIG on complement activation by deviating the classical pathway 
      activation towards the fluid phase. The prolonged survival of the IVIG-perfused 
      kidneys suggests that IVIG may be useful to dampen hyperacute rejection.
FAU - Fiane, A E
AU  - Fiane AE
AD  - Department of Surgery A, University of Oslo, The National Hospital, Norway.
FAU - Videm, V
AU  - Videm V
FAU - Mellbye, O J
AU  - Mellbye OJ
FAU - Foerster, A
AU  - Foerster A
FAU - Geiran, O R
AU  - Geiran OR
FAU - Gladhaug, I P
AU  - Gladhaug IP
FAU - Svennevig, J L
AU  - Svennevig JL
FAU - Mollnes, T E
AU  - Mollnes TE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Immunol
JT  - Scandinavian journal of immunology
JID - 0323767
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Peptide Fragments)
RN  - 80295-43-8 (Complement C3b)
RN  - 80295-50-7 (Complement C4b)
RN  - EC 3.4.21.41 (Complement C1r)
RN  - EC 3.4.21.42 (Complement C1s)
RN  - EC 3.4.21.47 (Complement C3 Convertase, Alternative Pathway)
SB  - IM
MH  - Animals
MH  - *Blood
MH  - Complement Activation
MH  - Complement C1r/metabolism
MH  - Complement C1s/metabolism
MH  - Complement C3 Convertase, Alternative Pathway
MH  - Complement C3b/metabolism
MH  - Complement C4b/metabolism
MH  - Female
MH  - *Graft Survival
MH  - Humans
MH  - Immunoglobulins, Intravenous/*pharmacology
MH  - In Vitro Techniques
MH  - Kidney Transplantation/*immunology
MH  - Male
MH  - Models, Biological
MH  - Peptide Fragments/metabolism
MH  - Perfusion
MH  - Swine
MH  - Transplantation, Heterologous
EDAT- 1998/07/04 00:00
MHDA- 1998/07/04 00:01
CRDT- 1998/07/04 00:00
PHST- 1998/07/04 00:00 [pubmed]
PHST- 1998/07/04 00:01 [medline]
PHST- 1998/07/04 00:00 [entrez]
AID - 10.1046/j.1365-3083.1998.00341.x [doi]
PST - ppublish
SO  - Scand J Immunol. 1998 Jun;47(6):568-74. doi: 10.1046/j.1365-3083.1998.00341.x.